Show simple item record

dc.contributor.authorSaran, F
dc.contributor.authorJames, A
dc.contributor.authorMcBain, Catherine A
dc.contributor.authorJefferies, S
dc.contributor.authorHarris, F
dc.contributor.authorCseh, A
dc.contributor.authorPemberton, K
dc.contributor.authorSchaible, J
dc.contributor.authorBender, S
dc.contributor.authorBrada, M
dc.date.accessioned2019-04-29T09:49:00Z
dc.date.available2019-04-29T09:49:00Z
dc.date.issued2018en
dc.identifier.citationSaran F, James A, McBain C, Jefferies S, Harris F, Cseh A, et al. Actr-38. A phase I trial of afatinib and radiotherapy (Rt) with or without temozolomide (Tmz) in patients with newly diagnosed glioblastoma (Gbm). Neuro-Oncology. 2018;20(suppl_6):vi20-vi.en
dc.identifier.doi10.1093/neuonc/noy148.071en
dc.identifier.urihttp://hdl.handle.net/10541/621798
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/neuonc/noy148.071en
dc.titleA phase I trial of afatinib and radiotherapy (Rt) with or without temozolomide (Tmz) in patients with newly diagnosed glioblastoma (Gbm)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentThe Royal Marsden, Suttonen
dc.identifier.journalNeuro-Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record